Multi-ancestry population attributable risk assessment of common genetic variation in Alzheimer's and Parkinson's diseases

 $\begin{array}{c} 1 \\ 1 \\ 2 \end{array}$ $\begin{array}{c} 1 \\ 1 \\ 2 \end{array}$ Lietsel Jones^{1,2}, Catalina Cerquera-Cleves^{3,4}, Artur FS Schuh^{5,6}, Mary B Makarious^{1,2}, Hirotaka

Iwaki^{1,2}, Mike A. Nalls^{1,2}, Alastair J Noyce^{7,}, Global Parkinson's Genetics Program (GP2), Cornelis

Blauwendr

$\frac{1}{2}$ \overline{a}

- Iwaki^{2,2}, Mike A. Nalls^{2,2}, Alastair J Noyce²⁷, Global Parkinson's Genetics Program (GP2), Cornelis
Blauwendraat^{1,8}, Andrew Singleton^{1,8}, Ignacio Mata⁹, Sara Bandres-Ciga¹
Affiliations:
1. Center for Alzhei Blauwendraat^{4,8}, Andrew Singleton^{4,8}, Ignacio Mata⁹
Affiliations:
1. Center for Alzheimer's and Related Dementia
National Institute of Neurological Disorders a
Bethesda, MD, USA.
2. DataTecnica LLC, Washington DC, , Sara Bandres-Ciga⁺
as (CARD), National I
ind Stroke, National
iit. Hospital Universii $\begin{array}{c} \mathbf{r} \\ \mathbf{r} \end{array}$ 1. Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and 1. Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and

National Institute of Neurological Disorders and Stroke, National Institutes of Health,

Bethesda, MD, USA.

2. DataTecnica LLC, Wash
	-
	-
	- National Institute of Neurological Disorders and Stroke, DataTecnica LLC, Washington DC, USA.
Department of Neurosciences, Neurology Unit, Hospital Universitario San Ignacio,
Bogotá, Colombia
CHU de Québec Research Center,
	- DataTecnica LLC, Wa
Department of Neuro
Bogotá, Colombia
CHU de Québec Rese
Canada
Departamento de Fa
Alegre, Brazil 3. Department of Neurosciences, Neurolo
Bogotá, Colombia
4. CHU de Québec Research Center, Axe N
Canada
5. Departamento de Farmacologia, Univer
Alegre, Brazil
6. Serviço de Neurologia, Hospital de Clíni 3. Bogotá, Colombia

	3. CHU de Québec Research Center, Axe Neurosciences, Université Laval, Quebec Cit

	3. Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Porto

	4. Alegre, Brazil

	5. Departamento
	-
	- CHU de Québec Re
Canada
Departamento de
Departamento de
Alegre, Brazil
Serviço de Neurolc
Centre for Prevent
University of Lond 4. Canada

	5. Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Porto

	Alegre, Brazil

	6. Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

	7. Centre for Preventive N Departa
Alegre, I
Serviço
Centre f
Universi
Laborato 5. Departamento de Farmacologia, Pincertamento de France do France do Regre, Brazil
6. Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
7. Centre for Preventive Neurology, Wolfson Institute Serviço de Ne
Centre for Pre
Centre for Pre
University of I
Genomic Mec
OH, United St Fractive Meurology, Wolfson Institute of Population Health, Queen

	University of London, London, UK.

	8. Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, I

	9. Genomic Medicine, Lerner Research
	-
	- 7. University of London, London, UK.

	8. Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA

	9. Genomic Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland,

	OH, Unite Laboratory of Neurogenetics, Nation
Genomic Medicine, Lerner Researc
OH, United States.
Jonding author
Jones
for Alzheimer's and Related Demer

֦ Corresponding author

9. Genomic Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Clevelan
OH, United States.
The Neuronal Institute on Aging and Aging and Aging sether for Alzheimer's and Related Dementias (CARD), NIA, NIH
The 9. Central Medicine, 20. General Medicine, Medicine, China Clinic Foundation, 2014
19. Genomic Medicine, Clinic Foundation, Clinic Foundation, California
19. Genomic Foundation, Clinic Foundation, Clinic Foundation, Clinic onding author
Jonding author
For Alzheimer's and
Conica LLC, Washing
Jondres. Ciga Center for Al;
Center for Al;
DataTecnica
email: <u>lietsel (</u>
Center for Al;
email: <u>sara.b;</u>

Center for Alzheimer's and Related Dementias (CARD), NIA, NIH
DataTecnica LLC, Washington DC, USA
email: <u>lietsel@datatecnica.com</u>
Sara Bandres-Ciga
Center for Alzheimer's and Related Dementias (CARD), NIA, NIH
email: <u>sar</u> email: <u>lietsel@datatecnica.com</u>
Sara Bandres-Ciga
Center for Alzheimer's and Related Der
email: sara.bandresciga@nih.gov
Keywords: genetic risk, population attr
ancestries. clinical trials. target prioriti; Sara Bandres-Ciga
Sara Bandres-Ciga
Center for Alzheimer's and Relat
email: <u>sara.bandresciga@nih.go</u>
Keywords: genetic risk, populati
ancestries, clinical trials, target p くくりょう Center for Alzheim
email: <u>sara.bandre</u>
Keywords: genetic
ancestries, clinical

Center for Alzheimer's and Related Dementias (CARD), NIA, NIH
email: <u>sara.bandresciga@nih.gov</u>
Keywords: genetic risk, population attributable risk, genome-wid
ancestries, clinical trials, target prioritization, Alzheimer Entertainment

Keywords: genetic risk, populatio

ancestries, clinical trials, target pr $\frac{1}{6}$ Keywords: genetic risk, population attributable risk, genome-wide association, diverse
ancestries, clinical trials, target prioritization, Alzheimer's disease, Parkinson's disease.
NOTE: This preprint reports new research

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Funding:
This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human
Services; project number ZIAAG000534, as well as the National Institute of Neurological
Disorders and Stroke (IFM received R01NS132437

Services; project number ZIAAG000534, as well as the National Institute of Neurological
Disorders and Stroke (IFM received R01NS132437-01A1).
C.C.C is funded by a Canadian Institutes of Health Research Vanier Scholarship.
 Disorders and Stroke (IFM received R01NS132437-01A1).
C.C.C is funded by a Canadian Institutes of Health Research Vanier Scholarship.
Conflicts of interest:
L.J., H.I, M.B.M, and M.A.N.'s participation in this project was C.C.C is funded by a Canadian Institutes of Health Researc
Conflicts of interest:
L.J., H.I, M.B.M, and M.A.N.'s participation in this project v
contract awarded to DataTecnica LLC by the National Insti
support open scienc Conflicts of interest:
L.J., H.I, M.B.M, and M.A.N.'s participation in this project was part of a competit
contract awarded to DataTecnica LLC by the National Institutes of Health to
support open science research. M.A.N. a (| (c _ c _ c _ c **Conflicts of interest:**
L.J., H.J. M.B.M. and M.A.N.'s participation in this project was part of a competitive

L.C.) They were availed to DataTecnica LLC by the National Institutes of Health to
support open science research. M.A.N. also currently serves on the scientific adviso
Clover Therapeutics and is an advisor and scientific f support open science research. M.A.N. also currently serves on the scientific
Clover Therapeutics and is an advisor and scientific founder at Neuron23 Inc
Acknowledgments: We thank all the participants who contributed to t support operators and is an advisor and scientific founder at Neuron23 Inc.
 Acknowledgments: We thank all the participants who contributed to this study. This work was

supported in part by the Intramural Research Progr **Acknowledgments:** We thank all the participants who contributed to this student supported in part by the Intramural Research Program of the NIH, the National Aging (NIA), the NIH, the US Department of Health and Human Ser $\begin{array}{c} \n\text{A} \\
\text{B} \\
\text{C} \\
\text{D} \\
\text{A} \\
\text{A} \\
\text{C} \\
\text{A} \\
\text{A} \\
\text{B} \\
\text{C} \\
\text{A} \\
\text{C} \\
\text{D} \\
\text{A} \\
\text{A} \\
\text{A} \\
\text{B} \\
\text{C} \\
\text{A} \\
\text{D} \\
\text{A} \\
\text{A} \\
\text{B} \\
\text{C} \\
\text{A} \\
\text{D} \\
\text{A} \\
\text{A} \\
\text{B} \\
\text{C} \\
\text{A} \\
\text{D} \\
\text{A} \\
\text{A} \\
\$ Acknowledgments: We thank all the participants who contributed to this study. This work was
supported in part by the Intramural Research Program of the NIH, the National Institute on
Aging (NIA), the NIH, the US Department

supported in and Human Services (project number
Aging (NIA), the NIH, the US Department of Health and Human Services (project number
ZIAAG000534), the National Institute of Neurological Disorders and Stroke (NINDS), and NH ZIAAG000534), the National Institute of Neurological Disorders and Stroke (NINDS), and N
We thank Paige Brown Jarreau for her meticulous editing of this manuscript.
This project was supported by the Global Parkinson's Gen We thank Paige Brown Jarreau for her meticulous editing of this manuscript.
This project was supported by the Global Parkinson's Genetics Program (GP2). Data (DOI
10.5281/2enodo.13755396, release 8) used in the preparation This project was supported by the Global Parkinson's Genetics Program (GP2)
10.5281/zenodo.13755496, release 8) used in the preparation of this article \
from GP2. GP2 is funded by the Aligning Science Across Parkinson's (ך
}
}
{| c 10.5281/zenodo.13755496, release 8) used in the preparation of this article were obtaine
from GP2. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and
implemented by The Michael J. Fox Foundation From GP2. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and
implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org). I
a complete list of GP2 members see https:/ from GP2. General distribution of the Michael J. Fox Foundation for Parkinson's Research (https://gp2.org
a complete list of GP2 members see https://gp2.org.
License: CC-BY implemented by The Michael School of GP2 members see https://gp2.org.
License: CC-BY
.

a complete list of GP2 members see https://gp2.org.
License: CC-BY \overline{a} License: CC-BY

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Abstract

Multiple scientific studies, improving our understanding of the molecular pathways implicated in the
(PD) etiologies, improving our understanding of the molecular pathways implicated in the
pathogenesis of these conditions many of the genetic factors associated with Alzheimer's disease (AD) and Parkinson's disease
(PD) etiologies, improving our understanding of the molecular pathways implicated in the
pathogenesis of these conditions. Howeve pathogenesis of these conditions. However, there is increasing evidence that the genetic
architecture of these diseases differs across ancestral populations. This raises concerns about
the efficacy of therapeutic intervent parchitecture of these diseases differs across ancestral populations. This raises concerns about
the efficacy of therapeutic interventions crafted around genetic targets prevalent only in
European ancestry populations. Suc the efficacy of therapeutic interventions crafted around genetic targets prevalent only in
European ancestry populations. Such interventions neglect potentially distinctive etiological
profiles, including Latino, Black/Afr European ancestry populations. Such interventions neglect potentially distinctive etiological
profiles, including Latino, Black/African American, and East Asian populations. In the current
study, we explore Population Attr profiles, including Latino, Black/African American, and East Asian populations. In the current
study, we explore Population Attributable Risk (PAR) in AD and PD etiologies and assess the
proportion of disease attributed to profiles, we explore Population Attributable Risk (PAR) in AD and PD etiologies and assess the proportion of disease attributed to specific genetic factors across diverse populations.
Leveraging data from genome-wide assoc stary, the implementary increases attributed to specific genetic factors across diverse populations.
Leveraging data from genome-wide association studies across four ancestries, we explore
distinct and universal therapeuti proveraging data from genome-wide association studies across four ancestries, we explore
distinct and universal therapeutic targets across diverse populations. Multi-ancestral genetics
research is critical to the developme Leveraging data interaction and universal therapeutic targets across diverse populations. Multi-ancestral genetics
research is critical to the development of successful therapeutics and treatments for
neurodegenerative dis research is critical to the development of successful therapeutics and treatments for
neurodegenerative diseases. By offering insights into genetic disparities, we aim to inform more
inclusive and effective therapeutic str reurodegenerative diseases. By offering insights into genetic disparities, we aim to inform more
inclusive and effective therapeutic strategies, advancing personalized healthcare.
Introduction
Alzheimer's disease (AD) and

Introduction

inclusive and effective therapeutic strategies, advancing personalized healthcare.

Introduction

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent

neurodegenerative disorders globally; their i inclusive and effective therapeutic strategies, advancing personalized healthcare.

Introduction

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent

neurodegenerative disorders globally; their i |
|
|
|
| Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent
neurodegenerative-disorders-globally; their-incidence-is-expected-to-triple-by-2050, particularly
in low-to-middle-income countries 1,2 . Gen in low to middle-income countries 1,2 . Genome-wide association studies (GWAS) have
uncovered key genomic regions associated with the risk and pathogenesis of these conditions
across diverse ancestries $^{3-10}$. These across diverse ancestries $3-10$. These advances are crucial for future therapeutic interventions
based on genetic targets, considering that drug mechanisms with genetic support have a 2.6x
higher probability of success t based on genetic targets, considering that drug mechanisms with genetic support have a 2.6x
higher probability of success than those without¹¹. Genetic evidence has proven particularly
valuable in areas where existing t higher probability of success than those without¹¹. Genetic evidence has proven particularly valuable in areas where existing treatments fail to modify disease progression, providing a solid foundation for developing ne foundation for developing new transformative drugs¹¹. However, the majority of GWAS on
neurodegenerative diseases predominantly feature participants of European ancestry,
underrepresenting the ancestral diversity of non underrepresenting the ancestral diversity of non-European populations¹². There is an urgent

underrepresenting the ancestral diversity of non-European populations¹². There is an urgent
need for improved drug development target selection and prioritization methods that consider
the different genetic architecture The different genetic architecture across all ancestries.

Population Attributable Risk (PAR) is a statistical measure used in epidemiology to estimate the

proportion of disease cases that would decrease if a risk factor Population Attributable Risk (PAR) is a statistical measure
proportion of disease cases that would decrease is
population ¹³. PAR estimates how much disease occ
factors, offering insights into disease pathophysiology
the proportion of disease cases that would decrease if a risk factor were removed from a
population ¹³. PAR estimates how much disease occurrence is influenced by particular risk
factors, offering insights into disease patho propulation ¹³. PAR estimates how much disease occurrence is influenced by particular risk factors, offering insights into disease pathophysiology and therapeutic strategies to mitigate these risks. In genetics, PAR repr population ¹³. PAR estimates how much disease occurrence is influenced by particular risk
factors, offering insights into disease pathophysiology and therapeutic strategies to mitigate
these risks. In genetics, PAR repre factors, these risks. In genetics, PAR represents a comparative means for comparing risk across genetic

loci relative to the odds ratio and frequency of the most representative variant(s) in a given

region. PAR serves to these risks. In general, these risks. In a given loci relative to the odds ratio and frequency of the most representative variant(s) in a given region. PAR serves to prioritize genetic targets according to their impact on location. PAR serves to prioritize genetic targets according to their impact on a specific
region. PAR serves to prioritize genetic targets according to their impact on a specific
3 region. Par serves to prioritize genetic targets according to their impact on a specific
3
3

population⁴⁴. By understanding PAR in the genetic context of AD and PD, healthcare strategies
and policies can be tailored to the specific needs of diverse population groups.
In this study, we aimed to comprehensively ex In this study, we aimed to comprehensively explore PAR estimates for com
factors associated with AD and PD through GWAS across various populations.
uncover disparities in genetic predispositions and their implications for ーイ しくられ factors associated with AD and PD through GWAS across various populations. Our goal was to uncover disparities in genetic predispositions and their implications for precision therapeutic development and applicability acros mother disparities in genetic predispositions and their implications for precision therapeutic
development and applicability across genetic ancestry groups in order to investigate distinct
and universal therapeutic targets development and applicability across genetic ancestry groups in order to investigate distinct
and universal therapeutic targets. Identifying these disparities may help the field to develop
more equitable and effective ther and universal therapeutic targets. Identifying these disparities may help the field to develop
more equitable and effective therapies, ensuring that therapeutic interventions are tailored to
the genetic makeup of diverse p and universal interpretations increments, and there are an particle targets in the senation of diverse populations.

The genetic makeup of diverse populations.

Methods

Data sources

Methods

more equitable and effective therapies, ensuring that therapeutic intervention in a function
the genetic makeup of diverse populations.
Data sources
Our reference datasets consisted of summary statistics from previously pu the genetic makeup of diverse populations.
 Nethods
 Data sources

Our reference datasets consisted of summary statistics from previously published population-

specific GWAS conducted in AD and PD across diverse genet |
|
|
|
| **ル(**SCS) Our reference datasets consisted of summary statistics from previously published population-Our reference datasets consisted of summary statistics from previously published populationspecific GWAS conducted in AD and PD across diverse genetically defined ancestries ^{5–10}. A
detailed summary of these data can be found in Table S1. To prevent the possible weakening of
associations or biased analyses, we detailed summary of these data can be found in Table 31. To prevent the possible weakening of
associations or biased analyses, we did not include summary statistics using proxy cases (those
from biobanks without a clinical From biobanks without a clinically defined case status). The variants in this study are
independent risk alleles and did not include those in linkage disequilibrium. All scripts for
analyses are publicly available on GitHu independent risk alleles and did not include those in linkage disequilibrium. All scripts for

analyses are publicly available on GitHub (DOI 10.5281/zenodo.13774456;

https://github.com/GP2code/PAR-ADPD/).
 Population A

analyses are publicly available on GitHub (DOI 10.5281/zenodo.13774456;

https://github.com/GP2code/PAR-ADPD/).
 Population Attributable Risk calculations

In this context, PAR is a measure of the risk reduction achieve **Example 19 Entries:**
 Analyses://github.com/GP2code/PAR-ADPD/).
 Population Attributable Risk calculations

In this context, PAR is a measure of the risk reduction achieved by hypothetically removing a

risk allele f **Population Attributable Risk calculations**
In this context, PAR is a measure of the ri
risk allele from the risk-associated locus
association and the frequency of the risk al
each dataset by $p < 0.05$ for nominally
enabl **Population Attributable Risk calculations**
In this context, PAR is a measure of the risk reduction achieved by hypothetically removing a risk allele from the risk-associated locus¹⁴. It is a combination of the magnitude of risk
association and the frequency of the risk allele. Before conducting PAR calculations, we filtered
each dataset by $p < 0.05$ for risk allele from the risk-associated locus²⁴. It is a combination of the magnitude of risk
association and the frequency of the risk allele. Before conducting PAR calculations, we filtered
each dataset by $p < 0.05$ for each dataset by $p < 0.05$ for nominally significantly associated variants. This refined filter enabled us to enhance confidence in the directionality of effect estimates for risk alleles and minimize potential sources of enabled us to enhance confidence in the directionality of effect estimates for risk alleles and
minimize potential sources of bias. We filtered summary statistics based on overlap with the
most significant disease variants minimize potential sources of bias. We filtered summary statistics based on overlap with the
most significant disease variants per locus from recent multi-ancestry GWAS models⁸. Odds
ratios (ORs) were computed from beta most significant disease variants per locus from recent multi-ancestry GWAS models⁸. Odds
ratios (ORs) were computed from beta estimates for each ancestry group contributing to the
GWAS meta-analysis. We standardized bet most significant disease variants per locus from recent multi-ancestry GWAS models^o
ratios (ORs) were computed from beta estimates for each ancestry group contributing
GWAS meta-analysis. We standardized beta estimates t to the
across
tion of
he risk
nt loci.
pective FOWAS meta-analysis. We standardized beta estimates to refer to the same effect allele across
different ancestries. These odds ratios were essential for assessing the strength and direction of
the association between singl different ancestries. These odds ratios were essential for assessing the strength and direction of the association between single-nucleotide polymorphisms (SNPs) and disease status. The risk allele frequency (RAF) was calc the association between single-nucleotide polymorphisms (SNPs) and disease status. The risk
allele frequency (RAF) was calculated across ancestries for SNPs representing significant loci.
This frequency was utilized in fu allele frequency (RAF) was calculated across ancestries for SNPs representing significant loci.
This frequency was utilized in further calculations of the PAR for each locus in the respective
populations.
We calculated PA This frequency was utilized in further calculations of the PAR for each locus in the respective
populations.
We calculated PAR using the formula:
 $PAR = \frac{p(OR-1)}{p(OR-1)+1}$ populations.

We calculated PAR using the formula:
 $PAR = \frac{p(OR-1)}{p(OR-1)+1}$

 μ is the calculate. $\frac{1}{2}$ We calculated PAR using the formula:

$$
PAR = \frac{p(OR-1)}{p(OR-1)+1}
$$

Where p represents the RAF and OR is the calculated odds ratio for each risk allele (OR > 1 , beta Where p represents the RAF and OR is the calculated odds ratio for each risk allele (OR > 1, beta > 0), both extracted from summary statistics under study. RAF values were plotted against their corresponding ORs for each ancestry group. a
: r

Results

 \overline{a} A total of 55 AD and 90 PD variants from GWAS meta-analyses^{3–10} were evaluated as
narrolation ethibutekle vide factors for European. Plash (African American Letine, and East population-attributable risk factors for European, Black/African American, Latino, and East Asian ancestries (Table S2, Table S3). Table S4 highlights the variants with the highest PAR estimates for both AD and PD in each population. population-attributable risk factors for European, Black/African American, Latino, and East t R

\overline{a} Cross-ancestry population attributable risk comparison reveals the universally applicable e genetic targets for Alzheimer's disease and Parkinson's disease

For AD, two loci had the highest PAR across multiple ancestries. The TSPAN14 locus For AD, two loci had the ingliest PAR across multiple ancestries. The TSPAN14 locus represented by the rs7922621 variant had one of the top signals in both European and d Black/African American ancestries. The rs9787874 variant at the PICALM locus also had one of the top PAR estimates in individuals of Latino, East Asian, Black/African American, and European ancestry (Figure 1)(Table S4). i
J d

**Correlated proxies to rs429358 and rs7412, and derived from population summary statistics

Figure 1. Highest population attributable risk (PAR) for Alzheimer's disease-related variants in n Black/African American, East Asian, European, and Latino populations, respectively. The x-axis represents the risk allele frequency, and the y-axis represents the odds ratio, or effect size. The Figure 1. Highest population attributable risk (PAR) for Alzheimer's disease-related variants in s e

It is made available under a CC-BY 4.0 International license.

nearest gene for each variant is indicated by color with the size of each dot being corresponding g to the PAR value.

In relation to PD, different variants exhibited nominal significance in cross-ancestry PAR In relation to PD, unierent variants exhibited nominal significance in cross-ancestry PAR.
References: CMCA leave accessoried by the m2FC402 waivet was identified excess for DAD. estimates. SNCA locus represented by the rs356182 variant was identified among top PAR signals for European, African/Admixed, and Latino populations. Top hits in the MAPT locus were e identified among Latinos and Europeans, while higher PAR estimates in the SNCA locus were e found among individuals of Latino, European, African/African Admixed, and East Asian descent . Moreover, the rs10513789 variant at the MCCC1 locus was found among the top signals in the e African/African Admixed, European, and East Asian ancestry populations; and VPS13C rs2251086 was among the highest PAR estimates in all populations (Figure 2)(Table S4). C

Figure 2. Highest population attributable risk (PAR) for Parkinson's disease-related variants in n African/African Admixed, East Asian, European, and Eathlo populations, respectively. The x-axis represents the risk allele frequency, and the y-axis represents the odds ratio, or effect size. The nearest gene for each variant is indicated by color with the size of each dot being corresponding to the PAR value. Figure 2. Highest population attributable risk (PAR) for Parkinson's disease-related variants in e g

\overline{a} APOE, GBA1, and LRRK2 display varying population-attributable risks for AD and PD across s diverse ancestries

The APOE allelic variants (rs7412 and rs429358), widely recognized as the major genetic risk The APOE allelic variants (137412 and 13429358), widely recognized as the major genetic risk factors for AD, consistently demonstrated higher PAR estimates across all ancestries than other genetic loci (Figure 3). Notably, individuals of Black/African American and East Asian descent r
F t It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

exhibited the highest PAR values for both variants compared to other ancestries, whereas those e of European ancestry showed lower values for the rs1081105 variant (a proxy for rs429358)) than other ancestries. In addition, individuals of Latino ancestry displayed the lowest PAR for r APOE compared to other ancestries, with rs429358 emerging as the highest APOE variant in this group, and rs7412 not being present in the summary statistics under study (Table S4). s

Figure 3. Population attributable risk (PAR) comparison among assessed populations for known n disease variants: APOE, GBA1, and LRRK2, respectively. The x-axis represents the risk allele frequency, and the y-axis represents the odds ratio, or effect size. Figure 3. Population attributable risk (PAR) comparison among assessed populations for known e

On the other hand, GBA1 was identified as one of the top PAR signals in the African/African On the other hand, GBA1 was identified as one of the top PAR signals in the African/African n Admixed ancestry, primarily driven by the population-specific variant GBA1 rs3115534. In contrast, other coding variants demonstrated varying PAR estimates across ancestries (Table S5). PAR estimates for GBA1 rs76763715 tagging p.N370S were lower in Europeans and Latinos, as well as the estimates for the intronic GBA1 rs146532106 variant in the East Asian population (Figure 3)(Table S3). Low PAR estimates were observed for the LRRK2 variant rs76904798 in al ancestries assessed. e as well as the estimates for the intronic GBA1 rs146532106 variant in the East Asian population n
n l,

This study aimed to dissect the impact of cross-ancestral risk alleles for AD and PD at a This study allied to dissect the impact of cross-ancestral risk alleles for AD and PD at a population scale by assessing and comparing PAR for variants from GWAS meta-analyses across s diverse ancestries, including European, African, East Asian, and Latino. While PAR fractions have previously been studied for modifiable risk factors in neurodegenerative diseases^{15,16}, to the
hast of sure linearly describing in the first study to active to the PAP for AP/PP related sensitiv best of our knowledge, this is the first study to estimate the PAR for AD/PD-related genetic e e c

It is made available under a CC-BY 4.0 International license.

assessed the genetic variants with the greatest influence on risk of AD/PD based on PAR
estimations in a global setting.
In AD, East Asian and European ancestry populations exhibited the highest PAR estimates for
APOE comp estimations in a global setting.

In AD, East Asian and European ancestry populations exhibited the highest PAR estimates for

APOE compared to other populations, underscoring the well-established risk associated with

APO In AD, East Asian and Europea

APOE compared to other pop

APOE4 in these groups⁸. In

Black/African American popula

risk associated with APOE4 risl

populations carrying the APOI

nopulations with this same al |ノノ[rFFc *APOE* compared to other populations, underscoring the well-established risk associated with *APOE4* in these groups⁸. In contrast, *APOE* risk varies considerably among Latino and Black/African American populations. Re APOE4 in these groups⁸. In contrast, *APOE* risk varies considerably among Latino and Black/African American populations. Recent studies have provided insights into the differential risk associated with *APOE4* risk all APOE4 in these groups⁹. In contrast, *APOE* risk varies considerably among Latino and Black/African American populations. Recent studies have provided insights into the differential risk associated with *APOE4* risk all risk associated with *APOE4* risk alleles among populations of African ancestry. African-descent
populations carrying the *APOE4* allele have been found to have a lower AD risk than other
populations with this same allele risk associated with APOE4 risk ancies among populations of African ancestry. African descent
populations carrying the *APOE4* allele have been found to have a lower AD risk than other
populations with this same allele, s populations carrying the APOE4 allele have been found to have a lower AD risk than other
populations with this same allele, suggesting that the African ancestral genetic background
surrounding the APOE gene is associated w populations with the APOE gene is associated with a lower odds ratio for risk variants¹⁷. A recent study identified a protective locus for the APOE4 allele in African-descent populations, which significantly lowers the surrounding the *APOE* gene is associated with a lower odds ratio for risk variants²⁷. A recent
study identified a protective locus for the *APOE4* allele in African-descent populations, which
significantly lowers the r significantly lowers the risk for AD in *APOE4* carriers, in which the magnitude of the effect
decreased from 7.2 to 2.1 for African carriers of the *APOE4* allele carrying this protective locus
located 2MB from *APOE*. Th

significantly lowers the risk for AD in APOE4 carriers, in which the magnitude of the effect
decreased from 7.2 to 2.1 for African carriers of the *APOE4* allele carrying this protective locus
located 2MB from *APOE*. The decreased from 7.2 to 2.1 for African carriers of the APOE4 allele carrying this protective locus
located 2MB from *APOE*. The protective haplotype has a frequency of 12% in African ancestry
while being notably rare in Eur While being notably rare in Europeans, with a frequency of only 0.003%¹⁸.
Of note, *TRANK1*, a novel locus unraveled by a recent multi-ancestry meta-analysis in AD⁸,
emerged as one of the top estimated PAR loci in the while being notably rare in Europeans, with a trequency of only 0.003%²⁰.
Of note, *TRANK1*, a novel locus unraveled by a recent multi-ancestry
emerged as one of the top estimated PAR loci in the Black/African Ame
PAR as くらりとくし Of note, *TRANK1*, a novel locus unraveled by a recent multi-ancestry meta-analysis in AD^o
emerged as one of the top estimated PAR loci in the Black/African American ancestry in our
PAR assessment. *TRANK1* seems to play ין, r s
alt d PAR assessment. *TRANK1* seems to play an important role in African descent populations, as
previously identified through a gene-based analysis in a GWAS conducted on African
Americans¹⁰. Interestingly, this locus has a TAN assessment. TRANK1 seems to play an important role in African descent populations, as
previously identified through a gene-based analysis in a GWAS conducted on African
Americans¹⁰. Interestingly, this locus has als Americans¹⁰. Interestingly, this locus has also been highlighted in GWAS for schizophrenia and
bipolar disorders, with the latter being well known to increase the risk of AD. Other important
cross-ancestral AD loci that Americans²⁰. Interestingly, this locus has also been highlighted in GWAS for schizophrenia and
bipolar disorders, with the latter being well known to increase the risk of AD. Other important
cross-ancestral AD loci that being a measuredral AD loci that emerged in our study included TSPAN14 for European and
Black/African American ancestries, and PICALM in individuals of European, Latino, Black/African
American, and East Asian descent. Both

cross-ancestral AD loci that emerged in our study included 15/AN14 for European and
Black/African American ancestries, and *PICALM* in individuals of European, Latino, Black/African
American, and East Asian descent. Both o Black/African Affician ancestries, and PTCALM in individuals of European, Latino, Black/Affican
American, and East Asian descent. Both of these genes have been implicated in microglia
activation, highlighting this pathway American, and East Asian descent. Both of these genes have been implicated in microglia activation, highlighting this pathway as a potential therapeutic target¹⁸.
In PD, our study identified *SNCA*, *MCCC1*, *MAPT*, and activation, highlighting this pathway as a potential therapeutic target⁴⁵.
In PD, our study identified *SNCA, MCCC1, MAPT*, and *VPS13C* as the loot
PAR. Three of these loci are multi-signal, with different and significa In PD, our study identified SNCA, MCCC1, MAPT, and VPS13C as the loci displaying the highest ancestries based on PAR estimates. In contrast, the rs10748818 variant at the *GBF1* locus was
identified as the locus with the highest estimated PAR for the African/African Admixed
population. This gene seems to modulate identified as the locus with the highest estimated PAR for the African/African Admixed
population. This gene seems to modulate intracellular protein traffic, and variants in it have
also been associated with PD in Chinese population. This gene seems to modulate intracellular protein traffic, and variants in it have
also been associated with PD in Chinese populations¹⁹. HLA-DRB5 rs112485576 had the highest
estimated PAR for the East Asian also been associated with PD in Chinese populations¹⁹. HLA-DRB5 rs112485576 had the highest estimated PAR for the East Asian population. Variants in this locus have also been previously associated with ulcerative coliti associated with ulcerative colitis and Crohn's disease, suggesting a potential overlapping
genetic nexus with gut disturbances in PD²⁰. Of note, the PAR estimates for *GBA1* differ across
populations, with the populatio associated with gut disturbances in PD²⁰. Of note, the PAR estimates for *GBA1* differ across populations, with the population-specific *GBA1* rs3115534 variant having one of the highest PAR estimates for the African/Af genetic nexus with gut disturbances in PD². Of note, the PAR estimates for *GBA1* differ across
populations, with the population-specific *GBA1* rs3115534 variant having one of the highest
PAR estimates for the African/A populations, with the population-specific GBA1 133113534 variant having one of the ingliest
PAR estimates for the African/African Admixed ancestry, while other well-known coding *GBA1*
variants showed varying PAR estimates PAR estimates for the African/African Admixed ancestry, while other well-known coding GBA1
variants showed varying PAR estimates depending on the population. On the other hand, the
lower observed PAR estimates for the *LRR* variants of the *LRRK2* p.G2019S variant across ancestries are expected
since this variant is less common compared to the PD GWAS loci resulting in a smaller
population attributable influence⁹. These results highlight th lower observed TAR estimates for the LRRK2 p.3201933 variant across ancestries are expected
since this variant is less common compared to the PD GWAS loci resulting in a smaller
population attributable influence⁹. These since this variant is less common compared to the PD CMAS locating in a smaller population attributable influence⁹. These results highlight the role of key cross-ancestral signals 8 population attributable influence⁹
Population
Population . These results highlight the role of k ey cross-ancestral signals $\frac{1}{3}$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

importance of designing therapeutic approaches tailored to the unique genetic profiles of each
ancestry.
This study prioritized potential genetic targets across diverse ancestries by estimating the PAR
for genetic loci ass increastry.

This study prioritized potential genetic targets across diverse ancestries by estimating the PAR

for genetic loci associated with AD and PD risk. Identifying genetic risk variants with consistent

PARs across This study
for geneti
PARs acro
effectiven
this study
PAR estim
achieved ヿ f l ∈ t l c c The study processes presented with AD and PD risk. Identifying genetic risk variants with consistent
PARs across multiple ancestries highlights the promise of developing therapeutics with broader
effectiveness, surpassing FARs across multiple ancestries highlights the promise of developing therapeutics with broader
PARs across multiple ancestries highlights the promise of developing therapeutics with broader
effectiveness, surpassing the co effectiveness, surpassing the constraints of population-specific treatments. Some limitations in
this study include differences in sample sizes across populations assessed which may influence
PAR estimates. Future refineme this study include differences in sample sizes across populations assessed which may influence
PAR estimates. Future refinement of PAR for the purposes of highlighting genetic targets can be
achieved by utilizing subpopula PAR estimates. Future refinement of PAR for the purposes of highlighting genetic targets can be achieved by utilizing subpopulation summary statistics. Further, genotyping arrays have been primarily Eurocentric leading to achieved by utilizing subpopulation summary statistics. Further, genotyping arrays have been primarily Eurocentric leading to the potential of missed risk signals in underrepresented populations. PAR estimates may be impro primarily Eurocentric leading to the potential of missed risk signals in underrepresented
populations. PAR estimates may be improved with the use of whole genome sequencing data in
future genome-wide association studies. C propulations. PAR estimates may be improved with the use of whole genome sequencing data in
future genome-wide association studies. Consideration of genetic and other risk factors, such as
environmental, in the use of PAR population studies. Consideration of genetic and other risk factors, such as environmental, in the use of PAR could prove useful in future applications. Overall, our results indicate that concentrating on specific genetic environmental, in the use of PAR could prove useful in future applications. Overall, our results
indicate that concentrating on specific genetic loci could amplify the efficacy of targeted
medical interventions, ultimately environmental, in the useful interviewing preceduation intervals applify the efficacy of targeted
indicate that concentrating on specific genetic loci could amplify the efficacy of targeted
medical interventions, ultimatel

References

- indical interventions, ultimately serving a wider population.

References

1. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease

2. and other dementias, 1990-2016: a systematic a medical interventions, the Section Perferences

Meferences

1. GBD 2016 Dementia Collaborators. Global, regional, and natio

2016. Lancet Neurol. 2019;18(1):88–106. $\begin{array}{c} \n \frac{1}{2} \quad \text{and} \quad \frac{$ 1. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease 2016. Lancet Neurol. 2019;18(1):88-106.
- $\frac{1}{2}$ GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's 2. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinso
disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953.
- $3¹$ Foo JN, Tan LC, Irwan ID, et al. Genome-wide association study of Parkinson's disease in East 32. Asians. Hum. Mol. Genet. 2017;26(1):226–232.
4. Rizig M. Bandres-Ciga S. Makarious MB. et al. Ic
- Rizig M, Bandres-Ciga S, Makarious MB, et al. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023;22(11):1015-1025.
- $5₁$ Loesch DP, Horimoto ARVR, Heilbron K, et al. Characterizing the Genetic Architecture of Parkinson's Disease in Latinos [Internet]. Ann. Neurol. 2021; Available from: http://dx.doi.org/10.1002/ana.26153
- Shigemizu D, Mitsumori R, Akiyama S, et al. Ethnic and trans-ethnic genome-wide association 6. Shigemizu D, Mitsumori R, Akiyama S, et al. Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk. Transl. Psychiatry 2021;11(1):151. $\frac{1}{2021;11(1):151}$
- Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer's 7. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimeric etiology
disease and related dementias. Nat. Genet. 2022;54(4):412–436. α and α relationships and α relationships α
- 8. Lake J, Warly Solsberg C, Kim JJ, et al. Multi-ancestry meta-analysis and fine-mapping in Alzheimer's disease. Mol. Psychiatry 2023;28(7):3121–3132.
9. Nalls MA. Blauwendraat C. Vallerga CL. et al. Identification of nov
- Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet heurol. 2019;18(12):1091-1102.
- 10. Kunkle BW, Schmidt M, Klein H-U, et al. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol.
2021;78(1):102–113. $A = \begin{bmatrix} 2021, 78(1).102-113. \end{bmatrix}$
- 11. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success [Internet]. Nature 2024; Available from: http://dx.doi.org/10.1038/s41586-024-07316-0
- 12. Jonson C, Levine KS, Lake J, et al. Assessing the lack of diversity in genetics research across neurodegenerative diseases: a systematic review of the GWAS Catalog and literature [Internet]. medRxiv 2024;Available from: http://dx.doi.org/10.1101/2024.01.08.24301007
- 13. Wang T, Hosgood HD, Lan Q, Xue X. The Relationship Between Population Attributable Fraction and Heritability in Genetic Studies. Front. Genet. 2018;9:352.
- 14. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease; a meta-analysis of genome-wide association studies. Lancet 2011;377(9766):641-649.
- 15. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9):819-828.
- 16. Bothongo PLK, Jitlal M, Parry E, et al. Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. Lancet Reg Health Eur 2022;15:100321.
- 17. Rajabli F, Beecham GW, Hendrie HC, et al. A locus at 19q13.31 significantly reduces the ApoE ε 4 risk for Alzheimer's Disease in African Ancestry. PLoS Genet. 2022;18(7):e1009977.
- 18. Yang X, Wen J, Yang H, et al. Functional characterization of Alzheimer's disease genetic variants in microglia. Nat. Genet. 2023;55(10):1735-1744.
- 19. Zhao A, Li Y, Niu M, et al. SNPs in SNCA, MCCC1, DLG2, GBF1 and MBNL2 are associated with Parkinson's disease in southern Chinese population. J. Cell. Mol. Med. 2020;24(15):8744-8752.
- 20. Kars, M.E., Wu, Y., Stenson, P.D. et al. The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson's disease comorbidity. Genome Med 16, 66 (2024). https://doi.org/10.1186/s13073-024-01335-2 h_{th} , h_{th} , h_{th} , h_{th} , h_{th} and h_{th}